The total return over the past 12 months is -7.72% vs. +16.94% for the S&P 500. So far it's up -24.71% this year. Includes price appreciation + reinvested dividends.
| Category | 1Y (TTM) | 3Y | 5Y | 10Y | 15Y | 20Y |
|---|---|---|---|---|---|---|
| Price CAGR | (7.72%) | (2.89%) | +3.52% | (3.53%) | +21.91% | +4.12% |
| Total Return CAGR | (7.72%) | (2.89%) | +3.52% | (3.53%) | +21.91% | +4.12% |
| Revenue CAGR | +11.75% | +27.37% | +19.70% | +143.28% | +25.31% | +26.38% |
| Net Income CAGR | +71.27% | N/A | N/A | N/A | +25.55% | N/A |
| EPS CAGR | +69.17% | N/A | N/A | N/A | +12.62% | N/A |
| Free Cash Flow CAGR | N/A | N/A | N/A | N/A | N/A | N/A |
| Operating Cash Flow CAGR | +3.40% | N/A | N/A | N/A | N/A | N/A |
| Dividends CAGR | N/A | N/A | N/A | N/A | N/A | N/A |
Visualize historical growth rates over rolling horizons. Use the dropdown to select different metric vectors.
Acadia Pharmaceuticals Inc. (ACAD)
| Year | Start price | End price | ACAD Return | SPY Return | Outperformance |
|---|---|---|---|---|---|
| 2026(YTD) | $26.71 | $20.11 | (24.71%) | +14.51% | (39.22%) |
| 2025 | $18.35 | $26.71 | +45.56% | +17.72% | +27.84% |
| 2024 | $31.31 | $18.35 | (41.39%) | +24.89% | (66.28%) |
| 2023 | $15.92 | $31.31 | +96.67% | +26.19% | +70.48% |
| 2022 | $23.34 | $15.92 | (31.79%) | (18.17%) | (13.62%) |
| 2021 | $53.46 | $23.34 | (56.34%) | +28.74% | (85.08%) |
| 2020 | $42.78 | $53.46 | +24.96% | +18.37% | +6.59% |
| 2019 | $16.17 | $42.78 | +164.56% | +31.22% | +133.34% |
| 2018 | $30.11 | $16.17 | (46.30%) | (4.56%) | (41.74%) |
| 2017 | $28.84 | $30.11 | +4.40% | +21.70% | (17.30%) |
Start and end prices are split-adjusted closing prices. Total return includes reinvested dividends, so it can differ from the price change.
